Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have modeled several attractive scenarios, but will remain extremely disciplined in our decision-making as it relates to divestitures, acquisitions and ensuring that our core portfolio is strong and positioned for long-term success |
| As we continue to grow volume and cover -- are able to cover our fixed cost that has the benefit of increasing our margin |
| Overall, we were pleased to see continued solid demand in our markets and CHS' ongoing progress on our strategic priorities |
| Inpatient and outpatient volumes in the fourth quarter increased for both the commercial and Medicare books, reflecting the strong demand in our markets and targeted capital investments |
| Major accomplishments in the year included volume gains across all key services as we continue to see broad-based strength in demand |
| New access points, strong capacity management, defined workforce initiatives and investments to optimize our competitive position, make this growth possible |
| Same-store admissions increased 3.5% in 2023 and adjusted admissions were up 5.3%, driving same-store net revenue growth of 4.8% |
| In an effort to strengthen our workforce in 2023, our centralized clinical recruitment team continued to deliver strong results, and we finished the year with a net gain of more than 1,000 bedside nurses |
| Adjusted EBITDA for the full year increased 12.3%, and our margin expanded 100 basis points year-over-year when excluding the positive impact of pandemic relief funds in 2022 |
| When you consider a more than $200 million unanticipated increase in medical specialist fees and medical malpractice expense with a 150 basis point impact to margin, we view this performance as a clear sign of positive momentum |
| We are already seeing notable benefits, including improvements in a variety of quality metrics and operational benchmarks such as reductions in mental state |
| So I feel good about the future in our ability to manage that cost |
| And after standing up our shared services platform and new workflows at 15 of our facilities with no disruption in patient care, we are seeing improved visibility and insight as expected |
| We remain well positioned to meet our needs going forward with improved operations, and $637 million of borrowing capacity under our ABL |
| We have a strong compliance program across Medicare and every other payer source as well |
| Looking into 2024, we have much better visibility into these factors, while at the same time, we anticipate tailwinds from growth capital projects over the past 2 years, further reductions in contract labor, additional savings from cost control efforts and a full year's benefit from the recently expanded Mississippi Medicaid funding program |
| Tim Hingtgen The only thing I would add is, to your question is, could you throttle that back? Anything is certainly possible, but similar to what we did in 2023, we were very deliberate in our investments into the core business with the intention of, as Kevin said earlier, working on projects that will help us certainly drive stronger EBITDA performance, which is a benefit to the long-term value of the company and its shareholders |
| Note that we've begun receiving payments in the first quarter from the state of Mississippi for the expanded Medicaid funding program and expect significant further improvement in cash flows relative to where we finished 2023 |
| But in general, to try to counteract some of those adverse trends, we believe we're better positioned going forward to make sure that, that admitting physician's decision is more strongly represented |
| Same-store ER volume grew 1.1%, while surgeries increased a solid 5.1% |
| Overall, we were pleased with our performance on labor costs |
| On a same-store basis, net revenue was up 4.1% over the fourth quarter of 2022, driven primarily by a 3.6% increase in adjusted admissions and a 0.5% growth in net revenue per adjusted admission |
| We saw many other measures of quality care success including a 25% reduction in the overall mortality rate and a 48% improvement in postop respiratory failure rates |
| Based on these factors as well as operating results through the first 6 weeks of the year, we have a high degree of confidence in our ability to deliver on the guidance we have provided and look forward to providing updates in the coming quarters |
| We're also managing that pipeline relative to the gains in staffing so that when we are ready to activate the capital, bring it online, we have a cost-effective way to drive margin and payback on that capital investment |
| Many of them are not baked into our guidance, and give us the upside potential |
| I'd also point out that the work we've done on patient safety and quality over the years and the 89% reduction in serious safety events that Tim called out is very meaningful |
| We continue to invest in our core markets to accelerate growth prospects and further capture market share |
| Based upon the success of in-sourcing ED and hospitalist medicine initiatives are underway to in-source anesthesia services in select markets, and we believe we can scale these new capabilities effectively and as needed |
| During the quarter, we benefited from the recognition of approximately $40 million in increased EBITDA from the Mississippi Hospital access program, of which approximately half related to prior periods |
| Statement |
|---|
| There probably is, and we've factored in a little bit of a headwind on continued deterioration in payer mix |
| As we look ahead to '24, the malpractice environment overall, I think, is getting more difficult |
| What we had not anticipated as we started 2023 was that medical specialist fees would spike as high as they did midyear prior to our APP transaction and that we would face additional headwinds from higher medical malpractice expense and from the outsized growth in Medicare Advantage, as we have discussed in quarterly calls since then, leading to the results you see today |
| And I think there is a little bit of pressure in the industry at large |
| The slowdown of receiving payments from Medicare Advantage payers versus fee-for-service of approximately $10 million and the acceleration of interest payments resulting from our refinancing efforts of approximately $30 million |
| We expected that to come down in Q4, particularly as we claw back some of the built up AR from our Cerner conversions |
| And here, there is some pressure there |
| We're still settling a lot of old claims, but the rate at which new claims are coming in is significantly lower than it had been historically |
| It was a negative in 2023 |
| We did not see the expected improvement sequentially in accounts receivable, primarily from the temporary billing delays that we discussed last quarter related to clinical system upgrades and our physician in-sourcing initiative |
| Is there anything you can tell in terms of rebound post pandemic and so forth that may show different trends across those payer classes? Kevin Hammons I think kind of post pandemic, we certainly saw a deterioration in the actions by the MA payers where they were not downgrading or denying claims during the pandemic, they certainly began denying and downgrading significantly more claims, particularly in the MA book, although it applies to commercial as well, but more so in the MA space |
| So that was all in, call it, roughly $130 million headwind in cash flow in the fourth quarter |
| Additionally, performance for the quarter was affected by growth in the Mississippi supplemental Medicaid program, AR of approximately $40 million |
| So we've not anticipated, we've not put that in our guidance this year as well as the tax refund, which we still feel very comfortable that we're going to get, but we were wrong |
| We expect further opportunities in the coming quarters as we look to scale our in-sourcing efforts, but believe there continues to be pressure, particularly in the area of anesthesia |
| I was wrong about anticipating the timing of that last year |
| The realization is really where we lose money comparatively and that's what causes the discount that we talked about, and that's a result of downgrades and denials of claims |
| Kevin Hammons Jason, I think we may have lost you |
| We also had with Mississippi coming in, which was unexpected in the fourth quarter, we did not want to appear that we were cherry picking and only adjusting out unfavorable items |
| So I think we've baked in a conservative estimate into '24 for wage inflation and we'll certainly work harder to keep it below that, and we're actually exiting '24 at a rate below that |
Please consider a small donation if you think this website provides you with relevant information